[A26-36] Depemokimab (asthma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2026
Project no.:
A26-36
Commission:
Commission awarded on 01.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Add-on maintenance treatment for patients with severe asthma with type 2 inflammation who are inadequately controlled despite high-dose inhaled corticosteroids and another controller
- Patients 12 to 17 years of age: added benefit not proven
- Adult patients: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-36
| Project no. | Title | Status |
|---|---|---|
| A26-37 | Depemokimab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V | Commission completed |